Literature DB >> 10877010

The pharmacokinetics of caffeine in Nigerian children suffering from malaria and kwashiorkor.

O O Akinyinka1, A Sowunmi, R Honeywell, A G Renwick.   

Abstract

OBJECTIVES: Caffeine-containing beverages are generally consumed by Nigerians suffering from malaria and kwashiorkor in the belief that caffeine aids early recovery from these illnesses, which are common in the tropics. However, there are no studies on the influence of these diseases on the absorption and pharmacokinetics of caffeine in Africans.
MATERIALS AND METHODS: A single oral dose of caffeine was given to five healthy children and to five and seven children suffering from malaria and kwashiorkor, respectively. Caffeine and its dimethylxanthine metabolites were measured in plasma using high-performance liquid chromatography.
RESULTS: The maximum plasma concentration (Cmax) of caffeine and the time of Cmax were similar (P > 0.05) in the three groups. However, the elimination half-life of caffeine was significantly longer in children with malaria (9.2 +/- 3.5 h) (P < 0.01) and kwashiorkor (13.1 +/- 7.9 h) (P < 0.05) than in the healthy controls (3.7 +/- 1.8 h). The total plasma oral clearance of caffeine of 4.4 +/- 1.9 ml/min/kg in healthy children was significantly higher (P < 0.01) than in those with kwashiorkor (2.0 +/- 0.9 ml/min/kg) and malaria (1.6 +/- 1.0 ml/min/ kg) (P < 0.05). Paraxanthine was the principal metabolite in all the three groups with Cmax significantly higher in healthy children (1.3 +/- 0.3 microg/ml) than in children with malaria (0.8 +/- 0.4 microg/ml) (P < 0.05) and kwashiorkor (0.3 +/- 0.1 microg/ml) (P < 0.0001). CYP1A2 activity, measured by the plasma ratios of paraxanthine: caffeine, was significantly lower in kwashiorkor and malaria.
CONCLUSIONS: This study showed that the plasma kinetics of caffeine are significantly altered in malaria and kwashiorkor, and CYP1A2 activity was lower in these two disease groups.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10877010     DOI: 10.1007/s002280050734

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  11 in total

1.  Pharmacokinetics of Benznidazole in Experimental Chronic Chagas Disease Using the Swiss Mouse-Berenice-78 Trypanosoma cruzi Strain Model.

Authors:  Suzana Marques de Jesus; Leonardo Pinto; Fernanda de Lima Moreira; Glauco Henrique Balthazar Nardotto; Rodrigo Cristofoletti; Luísa Perin; Kátia da Silva Fonseca; Pauliana Barbêdo; Lorena Cera Bandeira; Paula Melo de Abreu Vieira; Claudia Martins Carneiro
Journal:  Antimicrob Agents Chemother       Date:  2021-01-20       Impact factor: 5.191

2.  Physiological Regulation of Drug Metabolism and Transport: Pregnancy, Microbiome, Inflammation, Infection, and Fasting.

Authors:  Edward T Morgan; Joseph L Dempsey; Sylvie M Mimche; Tracey J Lamb; Supriya Kulkarni; Julia Yue Cui; Hyunyoung Jeong; Angela L Slitt
Journal:  Drug Metab Dispos       Date:  2018-03-07       Impact factor: 3.922

3.  Impact of visceral leishmaniasis and curative chemotherapy on cytochrome P450 activity in Brazilian patients.

Authors:  Vera Lucia Lanchote; Roque Almeida; Aldina Barral; Manoel Barral-Netto; Maria Paula Marques; Natália V Moraes; Angela M da Silva; Tania M V Souza; Guilherme Suarez-Kurtz
Journal:  Br J Clin Pharmacol       Date:  2015-07-02       Impact factor: 4.335

4.  Prediction of the clearance of eleven drugs and associated variability in neonates, infants and children.

Authors:  Trevor N Johnson; Amin Rostami-Hodjegan; Geoffrey T Tucker
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

Review 5.  A systematic review of pharmacokinetics studies in children with protein-energy malnutrition.

Authors:  Kazeem A Oshikoya; Helen M Sammons; Imti Choonara
Journal:  Eur J Clin Pharmacol       Date:  2010-06-16       Impact factor: 2.953

Review 6.  Update information on drug metabolism systems--2009, part II: summary of information on the effects of diseases and environmental factors on human cytochrome P450 (CYP) enzymes and transporters.

Authors:  S Rendic; F P Guengerich
Journal:  Curr Drug Metab       Date:  2010-01       Impact factor: 3.731

7.  Influence of CYP2C8, CYP3A4, and CYP3A5 Host Genotypes on Early Recurrence of Plasmodium vivax.

Authors:  Anne C G Almeida; Maria C B Puça; Erick F G Figueiredo; Laila R Barbosa; Yanka E A R Salazar; Emanuelle L Silva; Marcelo A M Brito; André M Siqueira; José L F Vieira; Marcus V G Lacerda; Wuelton M Monteiro; Gisely C Melo
Journal:  Antimicrob Agents Chemother       Date:  2020-06-23       Impact factor: 5.191

8.  A Physiologically-Based Pharmacokinetic Framework for Prediction of Drug Exposure in Malnourished Children.

Authors:  Erik Sjögren; Joel Tarning; Karen I Barnes; E Niclas Jonsson
Journal:  Pharmaceutics       Date:  2021-02-02       Impact factor: 6.321

9.  Pathophysiological changes that affect drug disposition in protein-energy malnourished children.

Authors:  Kazeem A Oshikoya; Idowu O Senbanjo
Journal:  Nutr Metab (Lond)       Date:  2009-12-01       Impact factor: 4.169

10.  Effects of 16-week consumption of caffeinated and decaffeinated instant coffee on glucose metabolism in a randomized controlled trial.

Authors:  Keizo Ohnaka; Mizuko Ikeda; Takako Maki; Tomoko Okada; Takao Shimazoe; Masahiro Adachi; Masatoshi Nomura; Ryoichi Takayanagi; Suminori Kono
Journal:  J Nutr Metab       Date:  2012-11-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.